BPMC Blueprint Medicines
- 94.370
- +4.830+5.39%
- 93.900
- -0.470-0.50%
Blueprint Medicines News
Blueprint Medicines | 10-Q: Q3 2024 Earnings Report
Blueprint Medicines | 8-K: Blueprint Medicines Reports Third Quarter 2024 Results and Raises AYVAKIT® / AYVAKYT ® (avapritinib) Full Year Revenue Guidance
Blueprint Medicines | 10-Q: Q2 2024 Earnings Report
Blueprint Medicines | 8-K: Blueprint Medicines Reports Second Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
Blueprint Medicines | 10-Q: Q1 2024 Earnings Report
Blueprint Medicines | 8-K: Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT ® / AYVAKYT ® (avapritinib) Full Year Revenue Guidance
Blueprint Medicines | 10-K: FY2023 Annual Report
Blueprint Medicines | 8-K: Blueprint Medicines Reports Fourth Quarter and Full Year 2023 Results
Blueprint Medicines | 10-Q: Q3 2023 Earnings Report
Blueprint Medicines | 8-K: Blueprint Medicines Reports Third Quarter 2023 Results
Blueprint Medicines | 10-Q: Q2 2023 Earnings Report
Blueprint Medicines | 8-K: Blueprint Medicines Reports Second Quarter 2023 Results
Blueprint Medicines | 10-Q: Q1 2023 Earnings Report
Blueprint Medicines | 8-K: Blueprint Medicines Reports First Quarter 2023 Results
Blueprint Medicines | 10-K: FY2022 Annual Report
Blueprint Medicines | 8-K: Blueprint Medicines Reports Fourth Quarter and Full Year 2022 Results
Blueprint Medicines | 10-Q: Q3 2022 Earnings Report
Blueprint Medicines | 8-K: Blueprint Medicines Outlines 2027 Blueprint to Achieve Precision Medicine at Scale and Reports Third Quarter 2022 Financial Results at Investor Day 2022
Blueprint Medicines | 10-Q: Q2 2022 Earnings Report
Blueprint Medicines | 8-K: Blueprint Medicines Reports Second Quarter 2022 Results
No Data
